Fact CheckerSign in

NCT04209244Recruiting

Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia

Effect of Fish Oil Versus Placebo on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia - A Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 26 Dec 2019 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Acute lymphoblastic leukemia (ALL) is the most common malignant disease among children. Treatment results have improved over time due to intensive risk-adapted therapy and the 5-year survival rate is now above 90%. However, the burden of therapy has increased proportionally. Many children develop serious acute and chronic side effects, which impact on the patients expected lifespan and impair their quality of life as a result of therapy. Treatment with PEG-asparaginase and dexamethasone increases the levels of triglycerides and total cholesterol. Consequently, the incidence of hyperlipidemia is high during initial ALL therapy. Studies have suggested that hyperlipidemia is a risk factor for development of osteonecrosis, thrombosis and possibly acute pancreatitis. Long-chained marine omega-3 fatty acids, found in fish oil, decrease levels of triglycerides and total cholesterol in hyperlipidemic patients. Due to the high survival rate, it is of great interest to develop methods to reduce treatment related toxicities. The investigators hypothesise that daily intake of fish oil will prevent development of hyperlipidemia during ALL treatment phases with dexamethasone and PEG-asparaginase compared to placebo and that fish oil intake may reduce the incidence of severe adverse events related to ALL treatment.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
100 (estimated)
First submitted
19 Dec 2019
Start date
16 Dec 2019
Primary completion date
31 Jul 2023
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
NCT number
NCT04209244

What you commit to

  • Study type: Interventional
  • Planned participants: 100
  • From 16 Dec 2019 to the primary completion date, 31 Jul 2023
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients diagnosed with ALL, stratified to high risk (HR) after induction treatment or stem cell transplantation in the ALLTogether protocol

Who the study is looking for

  • Children (1-17.9 years) and young adults (18-45 years) diagnosed with ALL, stratified to very-low risk (VRL), intermediate risk low (IR-low) and intermediate risk high (IR-high) in the ALLTogether protocol.

Age in the registry: 1 year to 45 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Aalborg University Hospital
Coordinator of this site? Confirm its status
AalborgDenmarkNot yet recruiting
Aarhus University Hospital
Coordinator of this site? Confirm its status
AarhusDenmarkNot yet recruiting
Rigshospitalet
Coordinator of this site? Confirm its status
CopenhagenDenmarkRecruiting
Odense University Hospital
Coordinator of this site? Confirm its status
OdenseDenmarkNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.